Madrigal Pharmaceuticals, Inc. (MDGL) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en West Conshohocken, PA, United States. El CEO actual es William J. Sibold.
MDGL tiene fecha de IPO 2007-02-06, 528 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $12.04B.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing innovative therapeutic candidates for cardiovascular, metabolic, and liver diseases. The company's lead product, resmetirom, is a liver-directed selective thyroid hormone receptor-ß agonist currently in Phase III clinical trials for treating non-alcoholic steatohepatitis. Madrigal is also advancing MGL-3745 as a backup compound and has established a research, development, and commercialization partnership with Hoffmann-La Roche. Headquartered in West Conshohocken, Pennsylvania, the company is positioned to address significant unmet medical needs in serious metabolic and hepatic diseases.
